United Therapeutics Corporation (UTHR) - Financial and Strategic SWOT Analysis Review

Date: March 29, 2016
Pages: 52
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: U8855DC4622EN
Leaflet:

Download PDF Leaflet

United Therapeutics Corporation (UTHR) - Financial and Strategic SWOT Analysis Review
United Therapeutics Corporation (UTHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

United Therapeutics Corporation (UTC) develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension and infectious diseases. The company's products consist of prostacyclin analogues including Remodulin (treprostinil) injection and Tyvaso (treprostinil) inhalation solution; and Orenitram (treprostinil). Adcirca (tadalafil) is a phosphodiesterase type 5 (PDE-5) inhibitor and Unituxin (dinutuximab) is used for monoclonal antibody for oncologic applications are the other products. Its product candidates include monoclonal antibodies (mAbs), glycobiology antiviral agents and cell-based therapies. The company is also developing engineered lungs for transplantation in pre-clinical stage. The company manufactures its products in its facility in Silver Spring, Maryland. It operates in the US and markets its products across Europe, South America and Israel. UTC is headquartered in Maryland, the US.

United Therapeutics Corporation Key Recent Developments

Feb 25, 2016: United Therapeutics Corporation Reports 2015 Fourth Quarter And Annual Financial Results
Oct 27, 2015: United Therapeutics Reports Third Quarter 2015 Financial Results
Jul 28, 2015: United Therapeutics Reports Second Quarter 2015 Financial Results
Jun 29, 2015: Dean Judy D. Olian Joins the United Therapeutics Board of Directors
Apr 28, 2015: United Therapeutics Reports First Quarter 2015 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

United Therapeutics Corporation - Key Facts
United Therapeutics Corporation - Key Employees
United Therapeutics Corporation - Key Employee Biographies
United Therapeutics Corporation - Major Products and Services
United Therapeutics Corporation - Pharmaceutical Pipeline Products Data
United Therapeutics Corporation, Pipeline Products by Therapy Area
United Therapeutics Corporation, Pipeline Products by Development Phase
United Therapeutics Corporation - History
United Therapeutics Corporation - Company Statement
United Therapeutics Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

United Therapeutics Corporation - Business Description
United Therapeutics Corporation - Corporate Strategy
United Therapeutics Corporation - SWOT Analysis
SWOT Analysis - Overview
United Therapeutics Corporation - Strengths
Strength - Robust Portfolio of PAH Products
Strength - Therapeutic Platforms
Strength - Growth in Remodulin Product Sales
United Therapeutics Corporation - Weaknesses
Weakness - Confined Customer Base
Weakness - Patent Infringement Lawsuits
United Therapeutics Corporation - Opportunities
Opportunity - Market Potential: PAH
Opportunity - Research and Development Projects
Opportunity - Strategic Collaboration
United Therapeutics Corporation - Threats
Threat - Intense Competition
Threat - Influx of Generics
Threat - Rapid Technological Changes
United Therapeutics Corporation - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

United Therapeutics Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
United Therapeutics Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
United Therapeutics Corporation, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 25, 2016: United Therapeutics Corporation Reports 2015 Fourth Quarter And Annual Financial Results
Oct 27, 2015: United Therapeutics Reports Third Quarter 2015 Financial Results
Jul 28, 2015: United Therapeutics Reports Second Quarter 2015 Financial Results
Jun 29, 2015: Dean Judy D. Olian Joins the United Therapeutics Board of Directors
Apr 28, 2015: United Therapeutics Reports First Quarter 2015 Financial Results
Feb 24, 2015: United Therapeutics Reports 2014 Fourth Quarter And Annual Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

United Therapeutics Corporation, Key Facts
United Therapeutics Corporation, Key Employees
United Therapeutics Corporation, Key Employee Biographies
United Therapeutics Corporation, Major Products and Services
United Therapeutics Corporation, Number of Pipeline Products by Therapy Area
United Therapeutics Corporation, Number of Pipeline Products by Development Stage
United Therapeutics Corporation, Pipeline Products By Therapy Area and Development Phase
United Therapeutics Corporation, History
United Therapeutics Corporation, Other Locations
United Therapeutics Corporation, Subsidiaries
United Therapeutics Corporation, Key Competitors
United Therapeutics Corporation, Ratios based on current share price
United Therapeutics Corporation, Annual Ratios
United Therapeutics Corporation, Interim Ratios
United Therapeutics Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
United Therapeutics Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
United Therapeutics Corporation, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

United Therapeutics Corporation, Pipeline Products by Therapy Area
United Therapeutics Corporation, Pipeline Products by Development Phase
United Therapeutics Corporation, Performance Chart (2011 - 2015)
United Therapeutics Corporation, Ratio Charts
United Therapeutics Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
United Therapeutics Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Skip to top


Ask Your Question

United Therapeutics Corporation (UTHR) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: